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Abstract: Lynch syndrome (LS) is a hereditary cancer syndrome responsible for 3% of all endometrial
cancer and 5% in those aged under 70 years. It is unclear whether universal testing for LS in
endometrial cancer patients would be cost-effective. The Manchester approach to identifying LS in
endometrial cancer patients uses immunohistochemistry (IHC) to detect mismatch repair (MMR)
deficiency, incorporates testing for MLH1 promoter hypermethylation, and incorporates genetic
testing for pathogenic MMR variants. We aimed to assess the cost-effectiveness of the Manchester
approach on the basis of primary research data from clinical practice in Manchester. The Proportion
of Endometrial Tumours Associated with Lynch Syndrome (PETALS) study informed estimates
of diagnostic performances for a number of different strategies. A recent microcosting study was
adapted and was used to estimate diagnostic costs. A Markov model was used to predict long-term
costs and health outcomes (measured in quality-adjusted life years, QALYs) for individuals and their
relatives. Bootstrapping and probabilistic sensitivity analysis were used to estimate the uncertainty
in cost-effectiveness. The Manchester approach dominated other reflex testing strategies when
considering diagnostic costs and Lynch syndrome cases identified. When considering long-term
costs and QALYs the Manchester approach was the optimal strategy, costing £5459 per QALY gained
(compared to thresholds of £20,000 to £30,000 per QALY commonly used in the National Health
Service (NHS)). Cost-effectiveness is not an argument for restricting testing to younger patients or
those with a strong family history. Universal testing for Lynch syndrome in endometrial cancer
patients is expected to be cost-effective in the U.K. (NHS), and the Manchester approach is expected
to be the optimal testing strategy.
Keywords: Lynch syndrome; endometrial cancer; reflex testing; cost-effectiveness analysis; decision
analytic model
1. Introduction
Lynch syndrome is an inherited cancer predisposition syndrome caused by pathogenic variants in
the DNA mismatch repair (MMR) genes. It has incomplete penetrance, which is also dependent on
which MMR gene is affected, but most individuals with Lynch syndrome face much higher risks of
colorectal cancer, endometrial cancer, and ovarian cancer than the general population [1]. There are
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generally no signs or symptoms of Lynch syndrome other than developing cancer. An individual is
generally regarded as having Lynch syndrome if they have a pathogenic MMR variant (path_MMR)
regardless of whether they have been diagnosed with an associated cancer.
As individuals with Lynch syndrome are more likely to develop colorectal and endometrial cancer,
the prevalence of Lynch syndrome is higher amongst those diagnosed with these cancers than in
the general population. Further, it is possible to test colorectal and endometrial tumours for signs
that Lynch syndrome may be implicated, as mismatch repair deficiency (dMMR) is associated with
Lynch syndrome and can be detected through molecular testing for microsatellite instability (MSI)
or through immunohistochemistry (IHC). Additionally, testing for hypermethylation of the MLH1
promoter region is able to rule out some sporadic cancers that demonstrate dMMR. Reflex (automatic)
testing of colorectal and endometrial cancer cases for possible Lynch syndrome, followed by referral for
diagnostic genetic testing, is a proven strategy for identifying individuals (and their family members)
with Lynch syndrome [2,3].
At present, testing for Lynch syndrome in endometrial cancer patients is not widespread in the
U.K. The U.K. health service is dominated by the National Health Service (NHS), which provides
healthcare mostly free of charge, paid for through general taxation (i.e., users are generally not required
to purchase social or private medical insurance). The different nations of the U.K. (England, Scotland,
Wales, and Northern Ireland) have different organisational systems, but in England (which accounts
for over 80% of the U.K. population) funding for healthcare mostly flows from the Department of
Health and Social Care, through NHS England, to regional clinical commissioning groups (CCGs) on
a capitation basis, and then onto hospitals and other providers on the basis of activity following a
national tariff. The National Institute for Health and Care Excellence (NICE) is currently assessing the
effectiveness and cost-effectiveness of such testing, but this paper presents an independent economic
evaluation not connected to the NICE assessment.
A number of studies have shown that reflex testing of colorectal cancer cases for Lynch syndrome
is effective and also cost-effective [4–8]. Demonstrating cost-effectiveness for reflex testing is important
to enable testing to be covered/reimbursed. More recent evidence has emerged that reflex testing
of endometrial cancer cases for Lynch syndrome may also be cost-effective [9–13], but much of this
evidence is limited in its scope, for example, most have not included the option of not testing for Lynch
syndrome as a comparator and have only compared testing strategies [9–12]. We recently published
a model-based economic evaluation using prevalence and diagnostic accuracy data estimated from
published literature [13], but this cannot adequately address that different testing strategies may not
only have different performance characteristics, but may also identify different Lynch syndrome cases
and face different challenges in a heterogeneous population. For example, MSI testing may both be
less specific in older patients (where somatic MLH1 hypermethylation is known to be more common
in colorectal cancer [14]) and may be less sensitive to identify path_MSH6 and path_PMS2 cases
(i.e., pathogenic variants in MSH6 and PMS2) [15].
The Proportion of Endometrial Tumours Associated with Lynch Syndrome (PETALS) study [16]
was conducted in a large U.K. gynaecological cancer centre to evaluate the effectiveness of reflex testing
in endometrial cancer cases and to estimate the prevalence of Lynch syndrome in this population.
A total 500 endometrial cancer cases were tested with IHC and MSI (300 recruited prospectively,
200 identified retrospectively having been consented for research), with MLH1 methylation testing and
germline next generation sequencing (NGS) being conducted where indicated. Sixteen women were
diagnosed with Lynch syndrome.
For an economic evaluation of reflex testing for Lynch syndrome in endometrial cancer patients to
be most valuable for decision makers, it should use reliable, consistent, and unbiased evidence for key
diagnostic performance parameters, and it should account for the differing values of identifying Lynch
syndrome cases according to their age and genotype.
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2. Methods
We performed an economic evaluation on the basis of patient-level data from the PETALS
study [16]. For each participant in PETALS, we simulated their diagnostic outcomes (and associated
costs) according to different diagnostic strategies. We used a Markov model to extrapolate the expected
lifetime costs and health outcomes for each participant on the basis of their diagnostic outcome.
These were combined, along with estimated costs and benefits of cascade testing for Lynch syndrome
in relatives of confirmed cases, to estimate the expected lifetime costs and quality-adjusted life years
(QALYs) for each diagnostic strategy, as well as to perform a cost-effectiveness analysis (see Table 1) to
determine the optimal strategy.
Table 1. Economic evaluation characteristics.
Decision Problem What is the Relative Cost-Effectiveness of Strategies to Identify LynchSyndrome in Women with Endometrial Cancer
Interventions and comparators
Strategy 0: No testing
Strategy 1: MSI triage followed by NGS
Strategy 2: MSI and MLH1 methylation testing triage followed by NGS
Strategy 3: IHC and MLH1 methylation testing triage followed by NGS (the
Manchester approach)
Strategy 4: Direct NGS
Type of economic evaluation, costs,
and health outcomes
Cost-effectiveness analysis: Diagnostic costs and Lynch syndrome cases identified
(no cost-effectiveness threshold identified)
Cost-utility analysis: Lifetime costs and QALYs for women with endometrial
cancer and their relatives (cost-effectiveness threshold £20,000 per QALY)
Model type Decision tree and Markov model implemented in R
Key data source PETALS study (diagnostic accuracy study conducted in Manchester)
Perspective NHS and PSS, costs in pounds sterling (£; GBP) in 2016/17 prices
Time horizon Lifetime
Discounting 3.5% for costs and QALYs
Analysis of uncertainty Non-parametric bootstrap resampling of participants in a clinical study andparametric sampling of model parameters (probabilistic sensitivity analysis)
MSI: microsatellite instability; IHC: immunohistochemistry; NGS: next generation sequencing; QALY: quality-
adjusted life years; PETALS: The Proportion of Endometrial Tumours Associated with Lynch Syndrome;
NHS: National Health Service; PSS: personal social services; GBP: (Great British) Pounds sterling (£).
2.1. Selection of Interventions and Comparators
2.1.1. The Manchester Approach
The Manchester approach uses a four-MMR protein immunohistochemistry panel to triage all
endometrial cancer cases. Where no assays indicate loss of expression, the case is discharged from
further testing for Lynch syndrome. If the tumour shows loss of MLH1 and/or PMS2 (but MSH2 and
MSH6 are expressed), MLH1 methylation testing is conducted on DNA from tumour cells and from
normal adjacent tissue. Cases showing hypermethylation in tumour cells are discharged from further
testing for Lynch syndrome. If the tumour shows loss of MSH2 and/or MSH6, or if the tumour shows
loss of MLH1 and/or PMS2 expression unexplained by MLH1 methylation, a NGS panel is used to
identify constitutional pathogenic variants in the MMR genes (and EPCAM).
Informed consent is obtained in the gynaecology clinic prior to NGS testing, but only patients in
whom a pathogenic MMR variant is found are referred for genetic counselling.
2.1.2. Comparator Strategies
The principal comparators to the Manchester approach (which is labelled strategy 3) that were
included in this evaluation are (see Figure 1a):
• No testing for Lynch syndrome in endometrial cancer cases (strategy 0);
• Triage by microsatellite instability testing, followed by NGS (strategy 1);
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• Triage by microsatellite instability testing, then MLH1 methylation testing, followed by NGS
(strategy 2);
• Direct NGS (strategy 4).
Figure 1. Model diagrams: (a) interventions and comparators in the economic evaluation;
LS: Lynch syndrome; MSI: microsatellite instability; MSI-H: microsatellite instability—high;
MSI-L; microsatellite instability—low; NGS: next generation sequencing; MSS: microsatellite stable;
IHC: immunohistochemistry; dMLH1: deficient MLH1 expression; dPMS2: deficient PMS2 expression;
dMMR: mismatch repair deficiency; pMMR: proficient mismatch repair. (b) Markov model structure
(self-links not shown for clarity); grey boxes in each health state give the utility value (QALY
(quality-adjusted life years) weight) for that state; U(Xi): utility value for individual I with characteristics
Xi; CRC: colorectal cancer.
Microsatellite instability testing typically includes a panel of five markers, and instability at two
or more of these is classed as microsatellite instability—high (MSI-H). Instability at a single marker
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is referred to as microsatellite instability—low (MSI-L). Instability in zero markers is referred to as
microsatellite stable (MSS). MSI is frequently caused by MLH1 promoter hypermethylation, but the
MSI markers have no diagnostic utility for recognising this, and thus either all MSI cases must undergo
methylation testing or none.
In addition to these comparators, we explored certain variations in scenario analyses:
• Using a two-MMR protein IHC panel (including only MSH6 and PMS2 antibodies);
• Treating MSI-L as indicative for further Lynch syndrome testing;
• Using clinical criteria (age or PREMM5 (PREdiction Model for gene Mutations, 5-gene version)
score [17]) to select patients at higher risk of having Lynch syndrome.
2.2. Economic Evaluation Approach
2.2.1. Diagnostic Testing
For each participant in the PETALS study, we simulated their diagnostic pathway according to
each diagnostic strategy. For example, if the tumour of a patient in PETALS had absent MSH6 but was
MSS, they would be simulated as discharged from further testing in strategies 1 and 2, even though in
PETALS they would have received further testing. Where MLH1 methylation testing was not ordered in
PETALS (on the basis of IHC results), it was assumed the test would not have shown hypermethylation.
Patients not undergoing NGS in PETALS were assumed not to have Lynch syndrome.
When an endometrial cancer patient (proband) is diagnosed with Lynch syndrome, cascade
testing of their relatives is simulated. For each proband, we modelled on average six relatives having
an appointment with a general practitioner in relation to Lynch syndrome, of whom 4.7 attended
genetic counselling, 3.3 underwent predictive genetic testing, and 1.5 were diagnosed with Lynch
syndrome [13]. The relatives were modelled irrespective of the true Lynch syndrome status and
diagnostic outcome for the proband, so that there was a consistent population across interventions.
2.2.2. Extrapolation
A Markov model was used to extrapolate future costs and health outcomes (measured in QALYs).
The Markov model was adapted from the model used by Snowsill et al. [13]. It was ported from Excel
to R [18] and built using the heemod package [19].
The Markov model included colorectal cancer as a downstream consequence of having Lynch
syndrome (diagnosed or undiagnosed) and colonoscopy as a risk-reducing intervention for those with
diagnosed Lynch syndrome. The incidence of colorectal cancer is modelled on the basis of which
(if any) MMR gene contains a pathogenic variant and the age of the individual [13]. For relatives,
the sex also influences the incidence of colorectal cancer [13]. Colonoscopy has been assumed to
directly reduce the incidence of colorectal cancer [8,20] and to make detection of colorectal cancer in
earlier stages more likely [8,21]. Colorectal cancer survival was modelled in terms of stage, with stage
IV having the worst prognosis and stage I the best. A model diagram is shown in Figure 1b.
The Markov model does not incorporate other Lynch syndrome-associated cancers, such as
future gynaecological cancer, cancers of the non-colorectal digestive tract, and cancers of the biliary
and urinary tracts [1]. It also does not include other preventative measures such as gynaecological
surveillance and aspirin chemoprevention, as these are not routinely used in clinical practice.
2.3. Methods for Estimating Costs
Costs are presented in 2016/2017 pounds Sterling (£; GBP), inflated using the Hospital and
Community Health Services Pay and Prices Index [22] to 2015/2016 and then by 1.1% to 2016/2017.
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2.3.1. Diagnostic Costs
The microcosting conducted by Ryan et al. [23] provided estimates for the majority of diagnostic
costs, however, we adjusted the unit costs to add on costs for staff time (as the original microcosting
included only staff salaries). This involved scaling labour costs by a factor of 2.08, and represented
additional costs of employers’ pension contributions, employers’ National Insurance Contributions,
and overheads (management, administrative and estates staff, non-staff overheads), but did not include
capital overheads. This was estimated by taking the average ratio of total cost (excluding capital
overheads) to salary for hospital-based scientific and professional staff in bands 4 to 7 [22].
We assumed that IHC with a two-MMR antibody panel would cost half the cost of the standard
test. This likely represents a best case scenario as there are likely to be some economies of scale. It was
assumed that filtering cases on the basis of age would not incur any cost. The cost of calculating,
recording, and communicating the PREMM5 score for a patient was assumed to be £3.58 (on the basis
of requiring 5 min of gynaecology registrar time) [22].
Costs for genetic counselling were estimated on the basis of Slade et al. [24], with post-test
counselling costing £133 (for both probands and relatives) and pre-test genetic counselling costing £172
for relatives. The Manchester approach follows the mainstreaming cancer genetics paradigm of not
offering pre-test genetic counselling for probands [25]. As a scenario analysis, we assumed counselling
costs of £428 for the first visit (post-test counselling for probands, pre-test counselling for relatives)
and £403 for a follow-up visit (post-test counselling for relatives) [26].
A summary of diagnostic costs is given in Table 2.
Table 2. Diagnostic testing unit costs.
Item Unit Cost (£, GBP) Source
Calculate PREMM5 score 3.58 PSSRU 2017 [22]
MMR IHC (4 protein panel) 30.36 1 Ryan et al. 2019 [23]
MMR IHC (2 protein panel) 15.18 Assumed half cost of 4 protein panel
MSI testing 36.63 1 Ryan et al. 2019 [23]
MLH1 methylation testing (strategy 2) 22.84 1 Ryan et al. 2019 [23]
MLH1 methylation testing (strategy 3) 32.65 1 Ryan et al. 2019 [23]
Obtain consent for NGS 13.64 1 Ryan et al. 2019 [23]
NGS 236.35 1 Ryan et al. 2019 [23]
Post-test genetic counselling (probands) 133.15 Slade et al. 2016 [24]
Pre-test genetic counselling (relatives) 171.73 Slade et al. 2016 [24]
Predictive genetic testing (relatives) 166.32 Slade et al. 2016 [24]
Post-test genetic counselling (relatives) 133.15 Slade et al. 2016 [24]
Key: IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; NGS, next generation
sequencing; PREMM5: PREdiction Model for gene Mutations, 5-gene version. Notes: 1 Labour costs scaled by 2.08
to include additional costs other than salary.
2.3.2. Long-Term Costs
The Markov model used to extrapolate long-term costs and outcomes includes costs for
colonoscopic surveillance and costs associated with colorectal cancer. Colonoscopies were assumed
to cost £583 [27], whereas the cost of colorectal cancer was dependent on the age of the patient and
stage of cancer at time of diagnosis, ranging from £807 (aged 80+, stage IV) to £14,490 (aged 40–49,
stage III) [28].
2.4. Methods for Estimating Health Benefits
2.4.1. Lynch Syndrome Cases Identified
For strategy 0 (no testing), we assumed no Lynch syndrome cases are identified. For strategy
1 (MSI triage), we assumed a true Lynch syndrome case would have been correctly identified if the
tumour demonstrated MSI-H. For strategy 2 (MSI and MLH1 methylation triage), we assumed a true
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Lynch syndrome case would have been correctly identified if the tumour demonstrated MSI-H and if
methylation testing showed no hypermethylation or was not conducted in the PETALS study (as this
would only be the case if IHC showed normal MLH1 expression). For strategy 3 (IHC and MLH1
methylation triage; the Manchester approach) we assumed a true Lynch syndrome case would have
been correctly identified if the tumour demonstrated complete (i.e., not patchy) absence of 1+ MMR
proteins, and that MLH1 methylation testing showed no hypermethylation or was not indicated.
For strategy 4 (direct NGS), we assumed that all true Lynch syndrome cases would be identified.
2.4.2. Long-Term QALYs
The Markov model used to extrapolate long-term costs and outcomes includes a baseline profile
for health-related quality of life that declines with age [29], as well as a loss of quality of life for those
with stage IV colorectal cancer (utility is scaled by 0.789, on the basis of a systematic review and
meta-regression [30]).
2.5. Methods for Handling Uncertainty and Heterogeneity
Our analyses naturally address heterogeneity in the patient population by projecting future costs
and outcomes for each participant in the PETALS trial individually on the basis of their age and MMR
genotype (sporadic/wildtype, path_MLH1, path_MSH2, path_MSH6, path_PMS2). We additionally
modelled a heterogeneous group of relatives by dividing a cohort of 310 relatives from the Wales regional
genetics service (personal communication, Dr Ian Frayling, Cardiff University, Cardiff, Wales, U.K.,
2012) into age quintiles, calculating the mean age for each of these (24.5, 35.7, 45.0, 53.2, and 66.8 years
of age, respectively) and simulating outcomes for men and women, starting at each of these ages with
each of the MMR genotypes (50 unique combinations).
Uncertainty is principally handled through a combined non-parametric bootstrap and probabilistic
sensitivity analysis approach. We performed 200 iterations, and in each of these iterations, the PETALS
population was resampled with replacement and the model was re-run for the resampled population
using values for each parameter sampled from probability distributions.
We explored a number of important scenario analyses to reflect alternative strategies for service
provision or key parameter assumptions. We explored whether it is cost-effective to apply clinical
criteria prior to testing, either restricting testing to those diagnosed with endometrial cancer under the
age of 70 or to those with a calculated PREMM5 score ≥ 2.5%. We also explored the cost-effectiveness
of testing under a “worst case” scenario, where the effectiveness of colonoscopic surveillance was
estimated from an Italian study [31] that showed the worst performance for surveillance in a systematic
review [32], and it was interpreted in the least favourable light to produce a hazard ratio for colorectal
cancer incidence of 0.929 (compared to a base case assumption of 0.387 [8,20]).
Our deterministic analyses utilised the full PETALS population and central estimates for parameter
values (and so incorporated heterogeneity but not parameter uncertainty), whereas our probabilistic
analyses incorporated heterogeneity and parameter uncertainty, as described above.
2.6. Further Details of Economic Evaluation
Table A3 gives further details of the inputs for the economic evaluation.
3. Results
3.1. Lynch Syndrome Cases Identified
As reported elsewhere [16], 16 Lynch Syndrome cases were identified amongst the 500 endometrial
cancer patients. These patients were younger than those with sporadic endometrial cancer—the mean
age for Lynch syndrome cases was 54 years versus 63.5 years for sporadic cases; 15 of 16 Lynch
syndrome cases were aged under 70 years versus 314 of 484 sporadic cases. Path_MSH6 variants
accounted for eight cases, whereas there were four path_MSH2 variants and two each of path_MLH1
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and path_PMS2. Detailed family history was available for 299 patients and allowed calculation of
PREMM5 score [17]; 11 of 13 Lynch syndrome cases with detailed family history had PREMM5 ≥ 2.5%,
as did 153 of 286 (53%) sporadic cases.
3.2. Cost per Lynch Syndrome Case Identified
In the PETALS study there were 16 cases of Lynch syndrome identified. Strategy 0 (no testing)
would not be expected to identify any of these, but would incur no cost. Strategies 1 and 2 (MSI-based
strategies) would be expected to identify nine of these, whereas strategy 3 (the Manchester approach)
and strategy 4 (direct NGS) would be expected to identify all of them. The Manchester approach
was the least expensive testing strategy and identified the most cases (tied with direct NGS, which
was the most expensive strategy). The MSI-based strategies were dominated by (more expensive
and less effective than) the Manchester approach and therefore not predicted to be cost-effective.
The Manchester approach was estimated to incur costs of £1700 per case of Lynch syndrome identified
(i.e., an ICER of £1700 per Lynch syndrome (LS) case identified). Table 3 shows the costs and cases
identified for each strategy.
Table 3. Deterministic base case cost-effectiveness analysis.
Strategy Costs (£) Effectiveness Outcome ICER
Short-term Diagnostic pathwaycosts 1
Lynch syndrome cases
identified 1
Additional diagnostic
pathway cost per Lynch
syndrome case identified
Strategy 0
No testing 0 0 —
Strategy 1
MSI 41,512 9 Dominated
Strategy 2
MSI and MLH1 methylation 27,523 9 Dominated
Strategy 3
IHC and MLH1 methylation 27,183 16 1699
Strategy 4
Direct NGS 127,125 16 Dominated
Lifetime
Lifetime costs
(proband/proband and
relatives)
Lifetime QALYs
(proband/proband and
relatives)
Additional cost per QALY
gained (proband
only/proband and relatives)
Strategy 0
No testing
120
642
7.64
104.61
—
—
Strategy 1
MSI
223
842
7.65
104.65
Dominated
Dominated
Strategy 2
MSI and MLH1 methylation
195
815
7.65
104.65
Extendedly dominated
3738
Strategy 3
IHC and MLH1 methylation
220
928
7.66
104.67
5003
5459
Strategy 4
Direct NGS
419
1128
7.66
104.67
Dominated
Dominated
Key: ICER, incremental cost-effectiveness ratio; IHC, immunohistochemistry; MSI, microsatellite instability; NGS,
next generation sequencing; QALY, quality-adjusted life year. Notes: 1 Calculated on the basis of PETALS population
(500 endometrial cancer patients). Strategies are arranged in ascending order of effectiveness. ICERs were calculated
versus the next most effective strategy on the cost-effectiveness frontier.
In the combined bootstrap and probabilistic sensitivity analysis, we found that the 95% credible
interval for the ICER of the Manchester approach versus no testing was £1117 to £3275 per LS case
identified, and that the Manchester approach dominated the other testing strategies with a probability
of 0.475.
When limiting to endometrial cancer cases aged < 70 years, the Manchester approach identified
15 Lynch syndrome cases (100% of those aged < 70 years). Strategy 2 (MSI and MLH1 methylation
testing triage) was the cheapest strategy, but only identified nine (60%) Lynch syndrome cases, and was
extendedly dominated by (more expensive and less effective than a combination of) the Manchester
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approach and strategy 0 (no testing). The Manchester approach costed £1300 per Lynch syndrome
case identified if testing only those aged < 70 years. When comparing universal reflex testing with
the Manchester approach to testing only those aged < 70 years, universal testing costed £7900 per
additional Lynch syndrome case detected.
When applying PREMM5 risk prediction and only testing those with a score≥ 2.5%, the Manchester
approach identified 11 (100%) Lynch syndrome cases. Strategy 2 (MSI and MLH1 methylation testing
triage) was the cheapest strategy but only identified eight (73%) Lynch syndrome cases, and was
extendedly dominated by the Manchester approach and no testing. The Manchester approach
costed £1100 per Lynch syndrome case identified when PREMM5 risk scoring was incorporated.
When comparing universal reflex testing with the Manchester approach to testing with PREMM5 risk
scoring, universal testing costed £2100 per additional Lynch syndrome case detected.
We found that IHC with a two-antibody (MSH6 and PMS2) panel would detect all 16 (100%) Lynch
syndrome cases in the PETALS study, and on the basis of the assumption that it would halve the cost
of IHC testing, it would also result in cost saving, costing £1200 per Lynch syndrome case identified.
Including MSI-L as a “test positive” in strategy 2 led to the identification of one additional
Lynch syndrome case and the requirement for further unnecessary testing in 20 patients, resulting
in an additional cost of £5600 per Lynch syndrome case identified versus only treating MSI-H as a
“test positive”. The Manchester approach still dominated MSI-based testing strategies.
3.3. Impact of Surveillance on Life Expectancy, Colorectal Cancer Outcomes, and QALYs
The Markov model predicts that identifying Lynch syndrome and putting surveillance in place
improves life expectancy, but the gain is dependent on which MMR gene is affected and the age of
the individual. For example, a 34-year-old proband with path_MLH1 would be expected to gain
4.3 years in life expectancy, whereas a 69-year-old proband with path_PMS2 would only be expected to
gain 0.4 years in life expectancy. The average life expectancy gain would be expected to be 1.8 years
amongst the probands with Lynch syndrome who are diagnosed and receive surveillance. The average
gain in life expectancy from surveillance for female relatives with Lynch syndrome was found to be
4.0 years, whereas it was found to be 3.5 years for male relatives.
The Markov model predicted that for the 16 women diagnosed with Lynch syndrome in
PETALS, surveillance would reduce the expected lifetime number of colorectal cancers from 6.3 to 3.2.
This included an increase in the number of stage I colorectal cancers from 1.2 to 2.2, and a reduction
in the number of colorectal cancers diagnosed in later stages (stage II: 3.1 to 0.4; stage III: 1.3 to 0.4;
stage IV: 0.7 to 0.3).
Surveillance was also predicted to improve lifetime QALYs (note that lifetime QALYs are
discounted at 3.5% per year, unlike life expectancy). Surveillance was expected to lead to a gain
of 0.6 QALYs on average amongst probands with Lynch syndrome, but this ranged from 0.05 to
1.38 QALYs, depending on age and genotype. The average gain in QALYs from surveillance for relatives
with Lynch syndrome was found to be 1.1 QALYs for women and 1.0 QALYs for men, with younger
relatives and those with path_MLH1 and path_MSH2 variants benefiting most.
3.4. Cost per QALY
When diagnostic outcomes were extrapolated into lifetime costs and health outcomes (measured in
QALYs) and combined with diagnostic costs, we found that strategies 1 and 4 were not cost-effective.
When we fixed model parameters at their central estimates, we predicted that the Manchester approach
would be cost-effective (see Table 3). When we considered only the endometrial cancer patients
themselves, the Manchester approach incurred on average £100 additional cost and generated an
average 0.020 QALYs, giving an ICER of £5000 per QALY gained. This gain in QALYs would be
inconsequential (it corresponds to around 1 week in perfect health), but it was concentrated in the
minority of patients who had Lynch syndrome, who gained, on average, 0.624 QALYs from the
Manchester approach. When we also included cascade testing of relatives, the Manchester approach
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incurred, on average,e £286 additional cost per endometrial cancer patient and had an ICER of £5500
per QALY (compared to strategy 2, which had an ICER of £3800 per QALY).
In the combined bootstrap and probabilistic sensitivity analysis, we found that the 95% credible
interval for the ICER of the Manchester approach versus no testing was £700 to £17,000 per QALY
gained (see Figure 2).
Figure 2. Cost-effectiveness acceptability curve for the Manchester approach versus no testing. This
figure shows, on the basis of how much a decision maker is willing to pay for 1 QALY, what the
probability is that the Manchester approach is cost-effective compared to no testing.
When testing was restricted to those aged < 70 years, the Manchester approach and strategy 2
(MSI and MLH1 testing triage) could be cost-effective, depending on the cost-effectiveness threshold.
The Manchester approach produced a greater health benefit at a cost of £5500 per QALY, and was
therefore cost-effective at a threshold of £20,000 per QALY. Comparing universal testing to only
testing those aged < 70 years, universal testing was cost-effective, costing an additional £12,900 per
QALY gained.
When PREMM5 risk scoring was included (with a threshold of 2.5%), we found that the Manchester
approach was cost-effective, producing the greatest health benefit at an additional cost of £6000 per
QALY gained relative to strategy 2 (the next best option). Universal testing was found to be cost-effective
compared to PREMM5 testing, costing an additional £11,700 per QALY gained.
When the effectiveness of colonoscopy was estimated from Arrigoni et al. 2005 [31], the cost-effectiveness
of testing worsened, as expected. Strategy 2 was found to be cost-effective at a threshold of £20,000
per QALY, whereas the Manchester approach was cost-effective with a threshold of £30,000 per
QALY. The Lynch syndrome cases identified by the Manchester approach but not strategy 2 were
mainly path_MSH6 cases (5/7) who had a lower risk of colorectal cancer than path_MLH1 and
path_MSH2 cases [33,34], and therefore they and their relatives already benefit less in absolute terms
from surveillance.
Using IHC with a two-antibody (MSH6 and PMS2) panel would (assuming that no Lynch
syndrome cases were missed) save approximately £15 per patient compared to using the full panel
with no change in QALYs.
Including MSI-L as a “test positive” would cost £9500 per QALY gained compared to only
considering MSI-H a “test positive”, but would be extendedly dominated by the Manchester approach,
and thus would not be cost-effective.
When the cost of genetic counselling was estimated from NHS reference costs for consultant-led
clinical genetics outpatient appointments, the Manchester approach remained cost-effective, costing £6700
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per QALY gained. The total average lifetime costs per participant (including any costs for relatives) were
increased by £60 over the base case where genetic counselling costs were taken from a costing study for
BRCA mutations.
4. Discussion
Our study suggests that the Manchester approach is cost-effective compared to no testing and
compared to other reflex testing strategies, costing around £5500 per QALY gained, and further that
universal testing (without restricting by age or predicting risk of Lynch syndrome using PREMM5)
is cost-effective. We found that restricting IHC testing to a two-antibody (MSH6 and PMS2) panel
would improve cost-effectiveness, but this finding was based on no Lynch syndrome cases failing
to display deficient expression for one of these proteins within PETALS, whereas other studies have
shown that a two-antibody panel is inferior to a four-antibody panel [35]. We found that including
MSI-L as a “test positive” result was not sufficient to make MSI-based testing cost-effective compared
to the Manchester approach.
The only current published study of reflex testing for Lynch syndrome in women with endometrial
cancer to include no testing as a comparator found that IHC and MLH1 methylation triage was
cost-effective, but costed approximately £14,000 per QALY gained for a 60-year-old endometrial cancer
patient, and was not cost-effective for patients aged 65 years and older [13]. The current study based
its extrapolation of long-term costs and QALYs on that study, and thus differences in cost-effectiveness
were driven by alternative assumptions regarding diagnostic testing, key amongst which are (i) lower
costs of IHC (and MSI and MLH1 methylation testing) on the basis of a microcosting study [23] rather
than estimates from pathologists and laboratory price lists, and (ii) not including pre-test genetic
counselling costs for probands.
This study has a number of strengths. As it was based on a single, large, high-quality trial,
it captured all of the associations between patient characteristics and tumour test results, such as
the relationship between age and MLH1 hypermethylation, and the possibility of differential test
performance for pathogenic variants in different MMR genes. This compares favourably to existing
modelling studies that have had to make assumptions about the performance across heterogeneous
groups [11–13]. The PETALS study itself has strengths, such as including a U.K. mixed metropolitan
population and being conducted in a non-insurance based system, meaning that there were minimal
barriers to participants consenting to germline testing [36]. The costs associated with diagnostic
testing were measured contemporaneously [23] in the same hospital, which contributed to high
internal validity.
The study also has some limitations that should be considered. PETALS identified 16 participants
with Lynch syndrome, but there were no cases detectable by MSI but not IHC. Such cases are
hypothetically possible and their absence in PETALS means that this possibility was not explored
through bootstrapping. Importantly, NGS was not conducted on all PETALS participants (although
it was conducted even if tumour tests did not demonstrate MMR deficiency in young patients and
those with suggestive family histories), and it was possible that a direct NGS strategy may have
identified additional pathogenic MMR variants. Further, as PETALS was a research study, participants
were consented for NGS upon entering the study, rather than being consented only after tumour
triage testing; it was possible that consenting for NGS at a different time-point could have resulted in
lower uptake.
A significant proportion of the value of identifying Lynch syndrome was to implement colonoscopic
surveillance to reduce the incidence and mortality due to colorectal cancer, however, the effectiveness
of colonoscopic surveillance has not been evaluated in an experimental setting. The Manchester
approach is more able to detect path_MSH6 cases (and likely more able to detect path_PMS2 cases)
than MSI-based testing, but these women are also at lower risk of colorectal cancer, and therefore if
colonoscopic surveillance is less effective than generally thought, testing for these cases and providing
surveillance may not be cost-effective.
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Our model to extrapolate long-term costs and benefits focusses on colorectal consequences of
Lynch syndrome, and does not model future gynaecological cancer or gynaecological surveillance in
relatives, nor does it model the cost or effect of aspirin (which may be used to reduce the incidence of
Lynch syndrome associated cancers [37]), nor does it model extra-colonic non-gynaecological cancers.
Although the methods employed in this study are broadly applicable, it is important to note
that there are frequently challenges to generalising the results of cost-effectiveness analyses to other
settings [38].
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Appendix A
Table A1. Details of model parameters.
Parameter Base Case Value Uncertainty (Distribution, 95% CI) 1
Population Characteristics
Prevalence of Lynch syndrome 3.20% Bootstrap, 1.96% to 5.68%
Prevalence of path_MLH1 0.40% Bootstrap, 0.03% to 1.41%
Prevalence of path_MSH2 0.80% Bootstrap, 0.24% to 2.03%
Prevalence of path_MSH6 1.60% Bootstrap, 0.68% to 3.19%
Prevalence of path_PMS2 0.40% Bootstrap, 0.02% to 1.33%
Age of Lynch syndrome cases (years) 54 Bootstrap, 47.0 to 60.9
Age of path_MLH1 cases 40.5 Bootstrap, 31.4 to 50.2
Age of path_MSH2 cases 53.8 Bootstrap, 44.7 to 62.3
Age of path_MSH6 cases 59.1 Bootstrap, 49.5 to 67.8
Age of path_PMS2 cases 47.5 Bootstrap, 16.6 to 79.5
Age of sporadic cases 63.5 Bootstrap, 62.4 to 64.6
Relatives per proband 6 Gamma, 1.80 to 11.96
Probability relative accepts counselling 77.70% Beta mixture, 73.8% to 81.1%
Probability relative accepts testing after counselling 71.60% Ratio, 67.4% to 76.4%
Probability relative has Lynch syndrome 44.00% Beta, 41.0% to 47.3%
Probability relative is female 52.80% Beta, 47.6% to 57.0%
Diagnostic Effectiveness
Strategy 1 sensitivity 0.563 Bootstrap, 0.256 to 0.818
Strategy 1 specificity 0.835 Bootstrap, 0.804 to 0.868
Strategy 2 sensitivity 0.563 Bootstrap, 0.256 to 0.818
Strategy 2 specificity 0.967 Bootstrap, 0.948 to 0.981
Strategy 3 sensitivity 1 Bootstrap, 1.000 to 1.000
Strategy 3 specificity 0.967 Bootstrap, 0.954 to 0.986
Disease Natural History
Colorectal cancer risk for proband aged 60 years to age 80 years 2,3
path_MLH1 39.50% Log-normal model, 33.5% to 47.4%
path_MSH2 35.70% Log-normal model, 28.9% to 42.1%
path_MSH6 19.90% Log-normal model, 12.1% to 28.1%
path_PMS2 10.20% Log-normal model, 1.3% to 30.2%
Sporadic 2.19% Not varied
Colorectal cancer risk for female relative aged 60 years to age 80 years 2,3
path_MLH1 30.80% Log-normal model, 24.1% to 40.1%
path_MSH2 27.00% Log-normal model, 20.5% to 36.3%
path_MSH6 12.80% Log-normal model, 6.9% to 22.7%
path_PMS2 5.50% Log-normal model, 0.5% to 24.9%
Sporadic 2.19% Not varied
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Table A2. Details of model parameters.
Parameter Base Case Value Uncertainty (Distribution, 95% CI) 1
Colorectal cancer risk for male relative aged 60 years to age 80 years 2,3
path_MLH1 35.20% Log-normal model, 28.7% to 43.8%
path_MSH2 31.40% Log-normal model, 23.8% to 40.7%
path_MSH6 16.30% Log-normal model, 9.5% to 26.2%
path_PMS2 7.70% Log-normal model, 0.9% to 30.7%
Sporadic 3.48% Not varied
5-year endometrial cancer mortality risk for probands 3
Lynch syndrome cases 10.40% Exponential model, 6.1% to 15.2%
Sporadic cases (x = age at diagnosis)
x < 45 12.40% Exponential model, 10.5% to 14.2%
45 ≤ x < 55 13.10% Exponential model, 11.9% to 14.5%
55 ≤ x < 65 14.50% Exponential model, 13.6% to 15.4%
65 ≤ x < 75 21.50% Exponential model, 20.7% to 22.5%
x ≥ 75 36.90% Exponential model, 35.3% to 38.9%
10-year other-cause mortality risk 3
Woman aged 60 7.60% Not varied
Woman aged 70 20.30% Not varied
Man aged 60 11.40% Not varied
Man aged 70 28.10% Not varied
5-year colorectal cancer mortality 3
Lynch syndrome case, by stage
Stage I 4.50% Exponential model, 2.1% to 8.0%
Stage II 15.80% Exponential model, 7.7% to 27.0%
Stage III 38.60% Exponential model, 20.8% to 59.2%
Stage IV 93.40% Exponential model, 92.9% to 93.9%
Sporadic case, by stage
Stage I 6.80% Exponential model, 6.1% to 7.5%
Stage II 22.90% Exponential model, 22.5% to 23.6%
Stage III 52.30% Exponential model, 51.7% to 53.0%
Stage IV 93.40% Exponential model, 92.9% to 93.9%
Colonoscopic Surveillance Effectiveness
Hazard ratio for incidence of colorectal cancer from
colonoscopic surveillance 0.387 Log-normal model, 0.164 to 0.753
Colorectal cancer stage distribution
Lynch syndrome case, under surveillance
Stage I 68.60% Dirichlet distribution, 52.9% to 81.8%
Stage II 10.50% Dirichlet distribution, 3.3% to 22.3%
Stage III 12.80% Dirichlet distribution, 5.0% to 23.4%
Stage IV 8.10% Dirichlet distribution, 1.8% to 18.8%
Lynch syndrome case, not under surveillance
Stage I 18.80% Dirichlet distribution, 9.2% to 34.2%
Stage II 48.80% Dirichlet distribution, 31.7% to 63.9%
Stage III 21.20% Dirichlet distribution, 10.7% to 32.8%
Stage IV 11.20% Dirichlet distribution, 4.1% to 22.8%
Sporadic case
Stage I 17.60% Dirichlet distribution, 17.2% to 18.0%
Stage II 27.00% Dirichlet distribution, 26.5% to 27.5%
Stage III 29.50% Dirichlet distribution, 29.1% to 30.0%
Stage IV 25.90% Dirichlet distribution, 25.4% to 26.4%
Utility Values
Baseline utility by gender and age (years)
Woman, 40 0.887 Regression model, 0.826 to 0.949
Woman, 50 0.855 Regression model, 0.766 to 0.944
Woman, 60 0.816 Regression model, 0.696 to 0.937
Woman, 70 0.77 Regression model, 0.611 to 0.931
Woman, 80 0.718 Regression model, 0.513 to 0.924
Woman, 90 0.659 Regression model, 0.403 to 0.917
Man, 40 0.909 Regression model, 0.845 to 0.974
Man, 50 0.876 Regression model, 0.787 to 0.968
Man, 60 0.837 Regression model, 0.717 to 0.963
Man, 70 0.791 Regression model, 0.630 to 0.954
Man, 80 0.739 Regression model, 0.534 to 0.945
Man, 90 0.68 Regression model, 0.424 to 0.938
Utility modifiers (multipliers)
Stage IV colorectal cancer 0.789 Beta, 0.721 to 0.844
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Table A3. Details of model parameters.
Parameter Base Case Value Uncertainty (Distribution, 95% CI) 1
Costs
Diagnostic costs
IHC £30.36 Gamma, £21.10 to £44.95
MSI £36.63 Gamma, £23.90 to £55.35
MLH1 methylation post-IHC £32.65 Gamma, £20.96 to £44.72
MLH1 methylation post-MSI £22.84 Gamma, £14.53 to £35.86
NGS £236.35 Gamma, £152.85 to £326.52
Post-test counselling (proband) £133.15 Gamma, £83.00 to £185.05
Consent to test (proband) £13.64 Gamma, £12.60 to £14.79
GP referral (relative) £36.40 Gamma, £24.16 to £48.46
Pre-test counselling (relative) £171.73 Gamma, £110.07 to £252.03
Predictive mutation testing (relative) £166.32 Gamma, £116.27 to £245.42
Post-test counselling (relative) £133.15 Gamma, £84.75 to £183.80
PREMM5 scoring £3.58 Gamma, £2.35 to £5.29
Surveillance costs
Colonoscopy £583.34 Gamma, £383.84 to £809.88
Interval between colonoscopies 2.1 years Log-normal, 1.54 to 2.89 years
Colorectal cancer costs (lifetime discounted costs, by stage and age)
Stage I, <50 £8754 Gamma, £5907 to £11,966
Stage I, 50–59 £5712 Gamma, £3793 to £7993
Stage I, 60–69 £4623 Gamma, £2990 to £6602
Stage I, 70–79 £3178 Gamma, £2125 to £4701
Stage I, ≥80 £1380 Gamma, £917 to £1868
Stage II, <50 £8741 Gamma, £5529 to £12,172
Stage II, 50–59 £7016 Gamma, £4367 to £10,348
Stage II, 60–69 £5352 Gamma, £3447 to £7751
Stage II, 70–79 £3455 Gamma, £2166 to £5124
Stage II, ≥80 £1546 Gamma, £923 to £2216
Stage III, < 50 £14,490 Gamma, £8742 to £21,370
Stage III, 50–59 £9692 Gamma, £6269 to £13,227
Stage III, 60–69 £7259 Gamma, £4500 to £10,369
Stage III, 70–79 £4485 Gamma, £2965 to £6123
Stage III, ≥80 £1561 Gamma, £1044 to £2424
Stage IV, <50 £11,705 Gamma, £7719 to £17,169
Stage IV, 50–59 £8444 Gamma, £5762 to £11,688
Stage IV, 60–69 £6509 Gamma, £4461 to £9038
Stage IV, 70–79 £4365 Gamma, £2636 to £5946
Stage IV, ≥80 £807 Gamma, £514 to £1097
1 Bootstrap 95% confidence intervals calculated using the normal approximation on a suitable transformed scale
(logit was preferred for proportions but arcsine was used when bootstrap iterations included 0 or 1). 2 Estimates
for those with Lynch syndrome are in the presence of colonoscopic surveillance. 3 Calculations conducted absent
competing risks.
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